Skip to contentE
Envoy Medical, Inc.
E
COCHEnvoy Medical, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$42.00K$42.00Kderived−55.8% vs Q4 2023 Net Income-$4.62M-$4.62MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Envoy Medical, Inc. · CIK 1840877 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,548,000N/M Operating Cash Flowderived-$5,091,000N/M Free Cash Flowderived-$4,557,000N/M Margins · derivedOperating margin-10828.6%−3751.7 pt vs Q4 2023
Net margin-10995.2%−5842.6 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end